STD molecular diagnostics market seen growing to $6.05 billion by 2030

The market for molecular diagnostics used to detect sexually transmitted diseases is projected to rise from $3.67 billion in 2025 to $4.07 billion in 2026, then reach $6.05 billion by 2030. Growth is being driven by rising STI cases, faster testing technologies and wider use of automated and point-of-care diagnostics.

Why it matters: - Molecular diagnostics can detect sexually transmitted infections earlier and more precisely than older testing methods. - Faster and more accurate STD testing can support quicker treatment, reduce transmission and improve outbreak control. - Rising STI case counts are increasing demand for testing capacity across healthcare systems.

What happened: - The Business Research Company released its Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on August 18, 2026. - The report projects the market will grow from $3.67 billion in 2025 to $4.07 billion in 2026. - The report forecasts the market will reach $6.05 billion by 2030. - The report places North America as the largest market in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period.

The details: - Molecular diagnostics for STDs test for the genetic material, DNA or RNA, of infectious agents. - The technology can detect infections even when symptoms are absent. - The report cites a 10.7% compound annual growth rate from 2025 to 2026. - The report projects a 10.4% CAGR through 2030. - Historical restraints included reliance on traditional serological testing, limited automated PCR availability, low awareness in emerging regions and manual, labor-intensive testing. - Growth drivers include automated PCR and nucleic acid extraction technologies, wider adoption of point-of-care molecular diagnostics, better healthcare infrastructure in developing countries, more use of laboratory information management systems and higher R&D spending on rapid multiplex tests. - Key trends include greater reliance on nucleic acid-based testing, more point-of-care platforms, demand for faster and more accurate STD detection, integration with LIMS and high-throughput automated PCR systems. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company offers a free sample of the report here. - The full report is available here.

Between the lines: - The market is benefiting from a shift away from slower, manual testing toward automated, higher-throughput diagnostics. - Rising STI diagnoses give the market a clear public-health use case, not just a commercial one. - The regional outlook suggests mature demand in North America and faster adoption potential in Asia-Pacific. - The report’s emphasis on LIMS and multiplex testing points to a market moving toward integrated lab workflows, not just standalone test kits.

What's next: - Adoption of point-of-care and automated molecular platforms is expected to keep expanding as health systems look for faster turnaround times. - The market’s next phase likely depends on continued investment in diagnostics infrastructure, especially in developing countries. - The report says demand should continue rising as healthcare providers prioritize early detection and more precise STI management.

The bottom line: - STD molecular diagnostics are moving from a specialist testing segment to a faster-growing, technology-led market tied closely to rising infection rates and lab automation.